Technical Analysis for ONCE - Spark Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| See historical ONCE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 10 | Crossed Above 20 DMA | Bullish | 0.00% |
| Dec 10 | Multiple of Ten Bullish | Other | 0.00% |
| Dec 10 | Outside Day | Range Expansion | 0.00% |
| Dec 7 | 180 Bearish Setup | Bearish Swing Setup | 7.35% |
| Dec 7 | Multiple of Ten Bearish | Other | 7.35% |
| Dec 4 | Fell Below 20 DMA | Bearish | 5.90% |
| Dec 4 | Multiple of Ten Bearish | Other | 5.90% |
| Dec 4 | Down 3 Days in a Row | Weakness | 5.90% |
| Dec 4 | Down 4 Days in a Row | Weakness | 5.90% |
| Dec 3 | 20 DMA Support | Bullish | -1.03% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ONCE news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 96.59 |
| 52 Week Low | 35.63 |
| Average Volume | 637,302 |
| 200-Day Moving Average | 64.7766 |
| 50-Day Moving Average | 44.7926 |
| 20-Day Moving Average | 40.69 |
| 10-Day Moving Average | 41.045 |
| Average True Range | 2.7808 |
| ADX | 26.4 |
| +DI | 17.1337 |
| -DI | 21.252 |
| Chandelier Exit (Long, 3 ATRs ) | 37.8276 |
| Chandelier Exit (Short, 3 ATRs ) | 43.9724 |
| Upper Bollinger Band | 43.8472 |
| Lower Bollinger Band | 37.5328 |
| Percent B (%b) | 0.62 |
| BandWidth | 15.518309 |
| MACD Line | -1.3573 |
| MACD Signal Line | -1.6287 |
| MACD Histogram | 0.2715 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.3 Billion |
| Num Shares | 31.3 Million |
| EPS | -6.39 |
| Price-to-Earnings (P/E) Ratio | -6.49 |
| Price-to-Sales | 124.29 |
| Price-to-Book | 11.08 |
| PEG Ratio | -0.59 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 46.49 | ||||
| Resistance 3 (R3) | 45.95 | 43.74 | 45.65 | ||
| Resistance 2 (R2) | 43.74 | 42.46 | 44.01 | 45.37 | |
| Resistance 1 (R1) | 42.60 | 41.67 | 43.17 | 43.14 | 45.09 |
| Pivot Point | 40.39 | 40.39 | 40.68 | 40.66 | 40.39 |
| Support 1 (S1) | 39.25 | 39.11 | 39.82 | 39.79 | 37.83 |
| Support 2 (S2) | 37.04 | 38.32 | 37.31 | 37.55 | |
| Support 3 (S3) | 35.90 | 37.04 | 37.27 | ||
| Support 4 (S4) | 36.44 |
